Cypralis has launched to focus on developing novel medicines for degenerative diseases

Cypralis Ltd has spun out from Selcia Ltd to focus on discovering novel medicines for acute and chronic degenerative diseases. Cypralis is focused on the discovery and development of highly innovative therapeutics for the modulation of peptidyl-prolyl isomerases known as PPIases, a large druggable family of protein targets involved in many acute and chronic diseases. Cypralis is seeking to establish collaborations with pharmaceutical and biotech companies to develop PPIase inhibitors for a number of degenerative diseases.